Logo

Innovent Signs a License Agreement with Union to Develop & Commercialize Orismilast for Inflammatory Dermatology Conditions in China

Share this

Innovent Signs a License Agreement with Union to Develop & Commercialize Orismilast for Inflammatory Dermatology Conditions in China

Shots:

  • Union to receive $20M up front and is eligible to receive ~$247M in milestone along with royalties on sales of orismilast in China & holds the global rights for the product outside of China
  • Innovent gets an exclusive license to research- develop and commercialize orismilast (PDE4 Inhibitor) in China- including participating and recruiting Chinese patients for global studies
  • In P-IIa clinical studies- orismilast demonstrated a superior profile with improved efficacy and tolerability. The therapy has provided POC data orally in psoriasis or AD & is well suited to address the unmet needs of the patient populations

  | Ref: PR Newswire | Image: Innovent

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions